Novartis Pharma US

      
Pseudomonas aeruginosa (Pa) infections are an important issue for people with cystic fibrosis.

Pseudomonas aeruginosa    infections are a
leading cause of decreased lung function in people with
cystic fibrosis. Knowing the facts about cystic fibrosis may
help with understanding the impact of Pseudomonas aeruginosa infections.
 
What is cystic fibrosis?
What are Pseudomonas aeruginosa infections?
Who gets Pseudomonas aeruginosa infections?
Are there symptoms of Pseudomonas aeruginosa infections?
How does TOBI treat Pseudomonas aeruginosa infections?
 
What is cystic fibrosis?
   

What’s the right way to say it? Click on the speaker icon Audio to hear how different words are pronounced. Make sure the speakers are turned up! These words are also defined in the glossary.

 
   

Ready to ask the doctor about Pseudomonas aeruginosa infections or treatments to help manage them?
Here are some conversation
starters
.

 
 
 
 
 
Home  |  CF and Pa Infections  |  TOBI Basics  |  Treating With TOBI  |  TOBI Tools and Tips
TOBI Patient Assistance  |  Cystic Fibrosis Resources  |  Glossary of Important CF Words  |  FAQs
Get More Information  |  Prescribing Information  |  Important Safety Information  | Send an E-card
CFvoice.com
Contact Us |  Site Map |  Site Guide

Please see full Prescribing Information.

Please see Patient Prescribing Information.

Information for Patients and Caregivers
Indication
TOBI® (Tobramycin Inhalation Solution, USP) is a prescription inhaled medication for cystic fibrosis patients whose lungs contain bacteria called Pseudomonas aeruginosa. TOBI has not been studied in patients under 6 years of age, in those with a lung function outside of a certain range, or in those whose lungs contain bacteria called Burkholderia cepacia. Ask your doctor if TOBI is right for you.

IMPORTANT SAFETY INFORMATION
If you are allergic to antibiotics in the same family as TOBI (ie, aminoglycosides), you should not take TOBI. Tell your doctor before starting treatment if you have any history of hearing, kidney, balance, or muscle problems.

Patients taking TOBI may have temporary side effects like coughing or difficulty breathing. Some people taking TOBI experienced ringing in the ears, hearing loss, or changes in voice (hoarseness)   . Ringing in the ears may be a warning sign for hearing loss. If you have ringing in the ears, changes in hearing, or dizziness, you should tell your doctor.

In studies, kidney damage was not seen in patients taking TOBI. However, antibiotics in the same family as TOBI have been linked to kidney damage.

If you are pregnant, plan to become pregnant, or if you are breast-feeding, talk with your doctor before taking TOBI.

Some drugs may interact with TOBI. Discuss all medications you are taking with your doctor.

Patients with cystic fibrosis can have many symptoms. Some of these may be related to your medications. You should tell your doctor if you have new or worsening symptoms.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

TBI-800101-B
Novartis Pharma US Use of Web site is governed by the Terms of Use and Privacy Statement.
Copyright © 2010
Novartis Pharmaceuticals Corporation. All rights reserved.
Novartis proudly supports the Patient Assistance Now program.